Myomo’s Strategic Turnaround: A Buy Rating with Revenue Growth and Operational Scaling on the Horizon

Myomo (MYO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.

Anthony Vendetti has given his Buy rating due to a combination of factors including Myomo’s continued growth in pipeline and backlog, and new developments in reimbursement procedures. Despite a lower than expected revenue in the first quarter of 2024, the company is positioned at a significant turning point with the implementation of the new CMS fee schedule on April 1, 2024. This change has led to immediate payments for the MyoPro units and is anticipated to accelerate the conversion of Medicare Part B patients to backlog, potentially expanding private payer coverage with the newfound reimbursement clarity. Myomo has also successfully increased its backlog by 56% in the first quarter, indicative of growing demand and operational scaling.
Moreover, Myomo’s financial position seems stable with sufficient cash reserves and no debt, alongside a strategic plan to enhance its manufacturing and reimbursement capabilities. The company’s international sales, which comprised a quarter of the quarter’s revenue, and the projected 80-100 MyoPro units per month production rate by year-end, further bolster Vendetti’s confidence in the stock. The revenue guidance for the second quarter and the full year of 2024 suggests a substantial year-over-year growth, reinforcing the Buy recommendation. The valuation appears compelling, with the stock trading at a premium to peers, which Vendetti believes is warranted given Myomo’s recent regulatory achievements and the significant market potential for the MyoPro.

In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $6.50 price target.

MYO’s price has also changed dramatically for the past six months – from $1.900 to $3.560, which is a 87.37% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Myomo (MYO) Company Description:

Myomo, Inc. is a medical robotics company, which offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. It offers MyoPro, which is a myoelectric elbow, wrist, and hand orthosis that supports an impaired hand and arm while also enabling it to move again. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Cambridge, MA.